The prevailing pandemic of SARS-CoV-2 highlights the desperate need of alternative
vaccine-platforms, which are safe, effective, and can be modified to carry antigens of …

The highly contagious SARS-CoV-2 Omicron subvariants severely attenuated the
effectiveness of currently licensed SARS-CoV-2 vaccines based on ancestral strains …

On November 7th and 8th, 2022, The National Institute of Allergy and Infectious Diseases
(NIAID), part of the National Institutes of Health (NIH), The Coalition for Epidemic …

A series of recombinant human type 5 adenoviruses that express the full-length or
membrane-truncated spike protein (S) of SARS-CoV-2 (AdCoV2-S or AdCoV2-SdTM …

Despite remarkable progress in the development and authorization of vaccines against
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is a need to validate …

Current coronavirus disease-19 (COVID-19) vaccines are administered by the intramuscular
route, but this vaccine administration failed to prevent severe acute respiratory syndrome …

Waning immunity and continued virus evolution have limited the durability of protection from
symptomatic infection mediated by intramuscularly (IM)-delivered mRNA vaccines against …

As the coronavirus disease 2019 (COVID-19) pandemic continues and new severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern emerge, the adaptive …

The global COVID-19 pandemic has sparked intense interest in the rapid development of
vaccines as well as animal models to evaluate vaccine candidates and to define immune …

Background A vaccine to protect against COVID-19 is urgently needed. We aimed to assess
the safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 (Ad5) …